The current boom in biotech IPOs makes it more important than ever for biologics developers to define safety and efficacy early and chart the proper course to market.
As promised in last week’s post, our white paper on meeting the unique challenges of biologics trials is now available for download. Reducing Risk in Biologics Trials: Targeted Trials for Targeted Therapeutics highlights differences between developing biologics and small molecules and presents solutions to some of the most pressing problems in biologics development.
I welcome your feedback on the white paper as well as trends in biologics development. I look forward to hearing from you.